A PYMNTS Company

US: FTC approves Teva-Allergan deal

By  |  July 28, 2016

Teva Pharmaceutical Industries Ltd won U.S. antitrust approval to buy Allergan Plc’s generics business, after agreeing to divest 79 generic drugs to rival firms, the Federal Trade Commission on July 26.

The $40.5 billion deal was announced in July 2015 and further solidifies Teva’s position as the world’s leading manufacturer of generics while freeing Allergan to focus on branded drugs.

Teva expects to close the transaction next week and has said that the combined company will have about 338 product registrations and will hold the leading position as the initial market entrant for around 115 pending U.S. generic drug applications.

Full Content: CNBC

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.